BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Havervall S, Ng H, Jernbom Falk A, Greilert-Norin N, Månberg A, Marking U, Laurén I, Gabrielsson L, Salomonsson AC, Aguilera K, Kihlgren M, Månsson M, Rosell A, Hellström C, Andersson E, Olofsson J, Skoglund L, Yousef J, Pin E, Lord M, Åberg M, Hedhammar M, Tegel H, Dönnes P, Phillipson M, Nilsson P, Klingström J, Mangsbo S, Hober S, Thålin C. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19. J Intern Med 2021. [PMID: 34459525 DOI: 10.1111/joim.13387] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Pooley N, Abdool Karim SS, Combadière B, Ooi EE, Harris RC, El Guerche Seblain C, Kisomi M, Shaikh N. Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review. Infect Dis Ther 2023;:1-21. [PMID: 36622633 DOI: 10.1007/s40121-022-00753-2] [Reference Citation Analysis]
2 Liu C, Zhang J, Zeng Y, Huang C, Chen F, Cao Y, Wu S, Wei D, Lin Z, Zhang Y, Zhang L, Teng J, Li Z, Hong G, Yang T, Ye H, Tu H, Xiao Y, Huang L, Lin C, Chen T, Deng Y, Ou Q, Li J. Effectiveness of SARS-CoV-2-inactivated vaccine and the correlation to neutralizing antibodies: A test-negative case-control study. J Med Virol 2023;95:e28280. [PMID: 36329648 DOI: 10.1002/jmv.28280] [Reference Citation Analysis]
3 Chen Q, Zhu K, Liu X, Zhuang C, Huang X, Huang Y, Yao X, Quan J, Lin H, Huang S, Su Y, Wu T, Zhang J, Xia N. The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis. Emerg Microbes Infect 2022;11:793-803. [PMID: 35195494 DOI: 10.1080/22221751.2022.2046446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Fevery J, Dallmeier K. Immunologische aspecten van Covid-19-ziekte en van vaccinatie tegen SARS-CoV-2 Deel 2: Variaties van het immuunantwoord individueel en in de tijd bij een infectie met SARS-CoV-2 en bij vaccinatie. Tijdschr Geneesk 2022. [DOI: 10.47671/tvg.78.22.112] [Reference Citation Analysis]
5 Soleimanian S, Alyasin S, Sepahi N, Ghahramani Z, Kanannejad Z, Yaghobi R, Karimi MH. An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19. Front Immunol 2022;13:884879. [PMID: 35669767 DOI: 10.3389/fimmu.2022.884879] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Pilz S, Theiler-Schwetz V, Trummer C, Krause R, Ioannidis JPA. SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity. Environ Res 2022;209:112911. [PMID: 35149106 DOI: 10.1016/j.envres.2022.112911] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 73.0] [Reference Citation Analysis]
7 Martínek J, Tomášková H, Janošek J, Zelená H, Kloudová A, Mrázek J, Ježo E, Král V, Pohořská J, Šturcová H, Maďar R. Immune Response 5–7 Months after Vaccination against SARS-CoV-2 in Elderly Nursing Home Residents in the Czech Republic: Comparison of Three Vaccines. Viruses 2022;14:1086. [DOI: 10.3390/v14051086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ceballo Y, López A, González CE, Ramos O, Andújar I, Martínez RU, Hernández A. Transient production of receptor-binding domain of SARS-CoV-2 in Nicotiana benthamiana plants induces specific antibodies in immunized mice. Mol Biol Rep. [DOI: 10.1007/s11033-022-07402-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Havervall S, Marking U, Greilert-Norin N, Gordon M, Ng H, Christ W, Phillipson M, Nilsson P, Hober S, Blom K, Klingström J, Mangsbo S, Åberg M, Thålin C. Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time. Clin Transl Immunology 2022;11:e1388. [PMID: 35444806 DOI: 10.1002/cti2.1388] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
10 Tabilo Valenzuela PBT, Flores Balter GF, Saint-pierre Contreras GS, Conei Valencia DC, Moreno Calderón CM, Bohle Venegas CB, Guajardo Rivera MG, Silva Ojeda FS, Vial Covarrubias MJV. Cellular Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination Schemes Authorized by the Chilean Ministry of Health in January 2022. Life 2022;12:534. [DOI: 10.3390/life12040534] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Marking U, Havervall S, Greilert Norin N, Bladh O, Christ W, Gordon M, Ng H, Blom K, Phillipson M, Mangsbo S, Smed Sörensen A, Nilsson P, Hober S, Åberg M, Klingström J, Thålin C. Correlates of protection, viral load trajectories and symptoms in BA.1, BA.1.1 and BA.2 breakthrough infections in triple vaccinated healthcare workers.. [DOI: 10.1101/2022.04.02.22273333] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
12 Şimşek M, Velioğlu Öcalmaz MŞ, Baştopçu M, Sargın M, Aksaray S. Cardiac surgery with cardiopulmonary bypass markedly lowers SARS-COV-2 antibody titer. Turk Gogus Kalp Dama 2022;30:160-166. [DOI: 10.5606/tgkdc.dergisi.2022.23347] [Reference Citation Analysis]
13 Laurén I, Havervall S, Ng H, Lord M, Pettke A, Greilert-Norin N, Gabrielsson L, Chourlia A, Amoêdo-Leite C, Josyula VS, Eltahir M, Kerzeli I, Falk AJ, Hober J, Christ W, Wiberg A, Hedhammar M, Tegel H, Burman J, Xu F, Pin E, Månberg A, Klingström J, Christoffersson G, Hober S, Nilsson P, Philipson M, Dönnes P, Lindsay R, Thålin C, Mangsbo S. Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology. Immun Inflamm Dis 2022;10:e595. [PMID: 35349756 DOI: 10.1002/iid3.595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Muskiet FAJ, Carrera-bastos P, Pruimboom L, Lucia A, Furman D. Obesity and Leptin Resistance in the Regulation of the Type I Interferon Early Response and the Increased Risk for Severe COVID-19. Nutrients 2022;14:1388. [DOI: 10.3390/nu14071388] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
15 Jotschke S, Schulze S, Jaekel N, Ludwig-kraus B, Engelmann R, Kraus FB, Zahn C, Nedlitz N, Prange-krex G, Mohm J, Peuser B, Schwarz M, Spohn C, Behlendorf T, Binder M, Junghanss C, Böttcher S, Al-ali HK. Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO). Cancers 2022;14:1544. [DOI: 10.3390/cancers14061544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Porto MH, Delgado T, Aguirre-jaime A, Ramos MJ, Campos S, Acosta O, Llanos AB, Lecuona M. Patients at risk of pulmonary fibrosis Post Covid-19: Epidemiology, pulmonary sequelaes and humoral response.. [DOI: 10.1101/2022.03.04.22271920] [Reference Citation Analysis]
17 Park U, Cho NH. Protective and pathogenic role of humoral responses in COVID-19. J Microbiol 2022;60:268-75. [PMID: 35235178 DOI: 10.1007/s12275-022-2037-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Marking U, Havervall S, Greilert-norin N, Ng H, Blom K, Nilsson P, Phillipson M, Hober S, Nilsson C, Mangsbo S, Christ W, Klingström J, Gordon M, Åberg M, Thålin C. Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines. Vaccines 2022;10:359. [DOI: 10.3390/vaccines10030359] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
19 Kountouras J, Gialamprinou D, Kotronis G, Papaefthymiou A, Economidou E, Soteriades ES, Vardaka E, Chatzopoulos D, Tzitiridou-chatzopoulou M, Papazoglou DD, Doulberis M. Ofeleein i mi Vlaptin—Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic. Medicina 2022;58:309. [DOI: 10.3390/medicina58020309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Nguyen M, Paul E, Mills PK, Paul S. Risk of COVID-19 Reinfection and Vaccine Breakthrough Infection, Madera County, California, 2021.. [DOI: 10.1101/2022.01.22.22269105] [Reference Citation Analysis]
21 Grgič Vitek M, Klavs I, Učakar V, Serdt M, Mrzel M, Vrh M, Fafangel M. Vaccine effectiveness against severe acute respiratory infections (SARI) COVID-19 hospitalisations estimated from real-world surveillance data, Slovenia, October 2021. Euro Surveill 2022;27. [PMID: 34991780 DOI: 10.2807/1560-7917.ES.2022.27.1.2101110] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Terpos E, Karalis V, Ntanasis-Stathopoulos I, Apostolakou F, Gumeni S, Gavriatopoulou M, Papadopoulos D, Malandrakis P, Papanagnou ED, Korompoki E, Kastritis E, Papassotiriou I, Trougakos IP, Dimopoulos MA. Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals. Hemasphere 2022;6:e677. [PMID: 34938959 DOI: 10.1097/HS9.0000000000000677] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
23 Havervall S, Marking U, Greilert-norin N, Gordon M, Ng H, Christ W, Phillipson M, Nilsson P, Hober S, Blom K, Klingström J, Mangsbo S, Åberg M, Thålin C. Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time.. [DOI: 10.1101/2021.10.16.21264948] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Mangsbo SM, Havervall S, Laurén I, Lindsay R, Jernbom Falk A, Marking U, Lord M, Buggert M, Dönnes P, Christoffersson G, Nilsson P, Hober S, Phillipson M, Klingström J, Thålin C. An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses. PLoS One 2021;16:e0258041. [PMID: 34591918 DOI: 10.1371/journal.pone.0258041] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]